PPA
AVTX icon

Parametric Portfolio Associates’s Avalo Therapeutics AVTX Stock Holding History

Parametric Portfolio Associates’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed -$35K – 3959
2019
Q3 		$35K Buy
+4
New +$44.6K ﹤0.01% 3912

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Parametric Portfolio Associates's AVTX Position: Q4 2019 in Review

Parametric Portfolio Associates sold out of Avalo Therapeutics (AVTX) in Q4 2019, closing a stake of 4 shares — an estimated $35K sold.

Parametric Portfolio Associates first reported a position in AVTX in Q3 2019 and held it in 1 quarter. The position peaked at $35K in Q3 2019. 37 funds tracked by Wall St. Rank hold AVTX as of Q4 2019.

  • Parametric Portfolio Associates reported no remaining Avalo Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Parametric Portfolio Associates sold 4 Avalo Therapeutics shares in Q4 2019, an estimated $35K.
  • Parametric Portfolio Associates first reported a position in Avalo Therapeutics in Q3 2019 and held it in 1 quarter.
  • Parametric Portfolio Associates's Avalo Therapeutics position peaked at $35K in Q3 2019.
  • 37 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2019.

Based on Parametric Portfolio Associates's 13F filing for Q4 2019, filed 14 Feb 2020.